Latest Conference Articles

January 19th 2019, 9:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

January 19th 2019, 8:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.

January 19th 2019, 11:40am

SGO Winter Meeting

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

January 19th 2019, 10:19am

SGO Winter Meeting

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

January 19th 2019, 5:55am

SGO Winter Meeting

Carolyn Lefkowits, MD, gynecologic oncologist, and palliative care doctor, at the University of Colorado, addresses common misconceptions regarding palliative care integration.

January 19th 2019, 3:33am

SGO Winter Meeting

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

January 19th 2019, 3:28am

Gastrointestinal Cancers Symposium (ASCO GI)

Daniela Molena, MD, discusses what she believes is the Achilles heel of endoscopic resection in patients with esophageal cancer.

January 19th 2019, 3:22am

SGO Winter Meeting

The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.

January 19th 2019, 3:19am

Gastrointestinal Cancers Symposium (ASCO GI)

Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.

January 19th 2019, 3:11am

SGO Winter Meeting

Katherine Kurnit, MD, OBGYN oncology fellow at the University of Texas MD Anderson Cancer Center, compares the benefit of gastrointestinal-based versus gynecologic-based adjuvant chemotherapy regimens in patients with mucinous ovarian cancer.

January 19th 2019, 12:44am

SGO Winter Meeting

Results from a recent retrospective study indicate that treatment with a gastrointestinal-based adjuvant chemotherapy regimen may be more beneficial than that of a gynecologic-based one in patients with mucinous ovarian cancer.

January 19th 2019, 12:41am

Gastrointestinal Cancers Symposium (ASCO GI)

Rachna T. Shroff, MD, MS, discusses the importance of molecular profiling upon diagnosis in patients with cholangiocarcinoma.

January 19th 2019, 12:02am

Gastrointestinal Cancers Symposium (ASCO GI)

Marcus Noel, MD, discusses the data of SM-88 and how it will impact the treatment of patients with metastatic pancreatic cancer.

January 18th 2019, 11:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of nivolumab and ramucirumab has activity in patients with previously treated advanced gastric adenocarcinoma, investigators reported at the 2019 Gastrointestinal Cancers Symposium.

January 18th 2019, 11:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

Allyson J. Ocean, MD, discusses her experiences with SM-88 in patients with metastatic pancreatic cancer.

January 18th 2019, 11:49pm

SGO Winter Meeting

Genomic testing to guide treatment decisions for women with ovarian cancer is in its early days. However, as more platforms become commercially available, physicians will need to understand the similarities and differences between tests.

January 18th 2019, 11:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab, trastuzumab, and chemotherapy.

January 18th 2019, 10:26am

SGO Winter Meeting

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

January 18th 2019, 9:26am

SGO Winter Meeting

Shannon N. Westin, MD, MPH, associate professor, The University of Texas MD Anderson Cancer Center, discusses advances made with PARP inhibitors in the ovarian cancer treatment paradigm.

January 18th 2019, 4:59am

Gastrointestinal Cancers Symposium (ASCO GI)

Pembrolizumab was found to reduce the risk of death by 31% in patients with PD-L1–positive advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy.